-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Swiss pharmaceutical giant Novartis (NVS.
US) announced financial results
for the third quarter of 2022.
During the reporting period, global sales revenue reached US$12.
54 billion, a year-on-year increase of 4% (in constant currency terms, the same below); In U.
S.
dollar terms, sales revenue decreased by 4%
year-on-year.
Source: Novartis financial report
Innovative Medicines (IM) and Sandoz both grew by 4%.
Among them, the Innovative Drugs segment generated $10.
3 billion in sales and its core growth-driven drugs included the heart failure/antihypertensive drug Noxinto (sacubitril valsartan) (+31%), the multiple sclerosis drug Quan Xinda (oxfatrumab, +172%), the breast cancer drug Kisqali (rebociclib, +49%) and the autoimmune disease drug Keshanding (skuchilumab, +7%)
.
Source: Novartis financial report
In addition, Pluvicto (lutetium lu 177 vipivotide), a targeted radioisotope therapy for the treatment of prostate cancer, has been approved in the United States and Europe
tetraxetan), third-quarter sales of $80 million
.
Source: Novartis financial report
Novartis Emerging Markets sales revenue increased 9% and China revenue increased 5% to $832 million
.
CEO Vasant
Narasimhan noted on the earnings call that this performance makes the company on track to become the top three pharmaceutical companies
in the Chinese market with annual sales revenue of $4 billion by 2024.
In addition, Narasimhan stressed that although the lockdown in the third quarter affected patients' purchases, China became one of
the main contributors to the drug's global performance.
Narasimhan also mentioned drugs currently in clinical development in China, including previtol and cholesterol-lowering therapy Leqvio (inclisiran), which he expects to become "blockbusters"
in the Chinese market once approved.
Novartis maintains growth momentum and confirms FY'22 Group guidance
